Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
78184.030.4432%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Gossamer Bio Inc

GOSSNASDAQ
Trade with Public
Trade with Public
$0.1701
N/A
At close: Aug 28, 5:00 PM EST
$0.1715
0.00140.82%
After Hours: 7:57 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Gossamer Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Gossamer Bio (GOSS).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

6Buy
2Hold
1Sell
Consensus RatingBuy# Analysts9Avg. Consensus PT$5Upside to Avg. PT+2832.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026Piper SandlerYasmeen RahimiPT CutOverweight$15→$4
Jul 28, 2026Leerink PartnersJoseph SchwartzUpgradeMarket Perform→Outperform$1
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.
Benzinga Newsdesk

This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. Analysts have positive views on FTH stock.
Avi Kapoor

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.
Avi Kapoor

PRO
Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1

Leerink Partners analyst Joseph Schwartz upgrades Gossamer Bio (NASDAQ:GOSS) from Market Perform to Outperform and maintains the price target from $1 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $2 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $2 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and lowers the price target from $5 to $2.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved